TCB-2
From Wikipedia, the free encyclopedia
TCB-2
|
|
Systematic (IUPAC) name | |
((8R)-4-bromo-2,5-dimethoxy-8-bicyclo[4.2.0]octa-1(6),2,4-trienyl)methanamine | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C11H14BrNO2 |
Mol. mass | 272.14 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
TCB-2 or (R)-(4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine is a conformationally resticted derivative of the phenethylamine derived hallucinogen 2C-B, discovered in 2006 by a team at Purdue University. It acts as a potent agonist for the 5HT2A and 5HT2C receptors with a Ki of 0.26nM at the human 5HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Br-DFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered.[1]
[edit] References
- ^ McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. Journal of Medicinal Chemistry. 2006 Sep 21;49(19):5794-803. PMID 16970404
|